CME Group (CME) is back in focus after reporting record June average daily volume of 30.6 million contracts and its second highest quarterly volume, alongside several new futures and options launches.

Despite CME Group’s record volumes and product launches, the stock’s recent momentum has been mixed, with the share price up 2.42% over one day and 7.06% over seven days but down 7.60% over 30 days and 22.45% over 90 days. At the same time, the 3-year total shareholder return of 47.87% and 5-year total shareholder return of 39.25% underline how sentiment can shift between short and long horizons.

If CME Group’s derivatives expansion has caught your attention, it may be a good moment to broaden your radar with a focused screener of 20 top founder-led companies

With CME Group shares falling 12.27% year to date despite record volumes, a stated 5.50% intrinsic discount, and a 27.28% gap to the average analyst target, is there still a buying opportunity here or is the market already pricing in future growth?

Most Popular Narrative: 21.8% Undervalued

With CME Group last closing at $236.60 against a narrative fair value of $302.60, the gap between price and modeled worth is clear and invites a closer look at the underlying thesis.

The ongoing global shift toward electronic trading, greater regulatory demands for transparency and standardized clearing, and a proven ability to grow non-transactional revenue (e.g., record market data revenue) position CME to capture a larger share of trading activity and support durable long-term earnings growth.

Want to see what is sitting behind that earnings story for CME Group? The narrative ties together steady top line assumptions, high margins and a valuation multiple that leans on those cash flows. Curious which specific growth and profitability targets have to line up to reach that fair value.

Result: Fair Value of $302.60 (UNDERVALUED)

However, CME Group’s reliance on derivatives tied to interest rates and equities, along with competitive pressure from crypto perpetual futures, could challenge both volumes and valuation assumptions over time.

Next Steps

Given the mixed signals around CME Group so far, it makes sense to act promptly and weigh the upside against the concerns using the full breakdown of 4 key rewards and 2 important warning signs

Looking for more investment ideas beyond CME Group?

If CME Group has sharpened your focus on quality opportunities, do not stop here. Use targeted stock ideas to pressure test and expand your portfolio thinking.

• Target dependable cash generators and stress test your watchlist against companies screened as 44 high quality undervalued stocks
• Prioritize resilience by scanning for companies flagged in the 74 resilient stocks with low risk scores
• Spot potential early movers by reviewing the screener containing 18 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.